BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 22
• 23
• 24
• 25
• 26
• 27
• 30
• 31

• Press Releases

  Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials

  March 24, 2026

   · 

  4 min read
• Press Releases

  Callio Therapeutics Doses First Patient in Phase I Clinical Trial of Dual-Payload ADC CLIO-8221 in Advanced HER2-Expressing Solid Tumors

  March 24, 2026

   · 

  4 min read
• Press Releases

  Applied StemCell and Cellipont Bioservices Partner to Offer a Seamless Path for iPSC-Derived Cell Therapy Development

  March 24, 2026

   · 

  4 min read
• Press Releases

  INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.

  March 24, 2026

   · 

  3 min read
• Press Releases

  Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company’s Scientific Advisory Board

  March 24, 2026

   · 

  4 min read
• Press Releases

  Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart

  March 24, 2026

   · 

  4 min read
• Press Releases

  KIFFIK Biomedical and HekaBio Announce Strategic Alliance to Expand ISF-Based Molecular Access Across Asia-Pacific

  March 24, 2026

   · 

  3 min read
• Press Releases

  Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

  March 24, 2026

   · 

  5 min read
• Press Releases

  20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program

  March 24, 2026

   · 

  5 min read
• Press Releases

  EpiFrontier Therapeutics Secures up to $32M Grant from the Japan Agency for Medical Research and Development to Advance Novel Therapy for Beta Globin Disorders

  March 24, 2026

   · 

  6 min read